BIOLOGICAL RESPONSE MODIFIERS

Biological response modifiers (BRMs) of current clinical interest may be divided into two categories: immunomodulating agents and colony sti mulating factors (CSFs). The first are employed to potentiate the host defences towards the tumor but results have proved disappointing in n on-small cell lung cancer (NSCLC). With regard to the second, the real dose increment which may be ascribed to CSFs is not sufficient to ove rcome chemoresistance of NSCLCs. CSFs can, however, reduce the hematol ogic toxicity of chemotherapy, which represents the most significant r esult.